Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
NCT00407459
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
77
Enrollment
OTHER
Sponsor class
Conditions
Mesothelioma
Interventions
DRUG:
Bevacizumab, Pemetrexed, Carboplatin
Sponsor
Armando Santoro, MD